LOS ANGELES--(BUSINESS WIRE)--Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq: OCUL) concerning possible violations of federal securities laws.
To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or by email at firstname.lastname@example.org.
On May 5, 2017, Ocular disclosed that the Food and Drug Administration found minor issues at its manufacturing plant, but downplayed any concerns. On July 6, 2017, Seeking Alpha published an article alleging that Ocular’s management has been misleading investors about manufacturing issues, including that more than half of lots manufactured by the Company contain bad product.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.